Navy Vet First to Get FDA Approved Procedure in L.A. for Degenerative Corneal Disease at USC Roski Eye Institute


Adam Lyons, a U.S. Navy service member, had LASIK surgery in 1997 to eliminate having to wear glasses or contacts. Shortly afterward, Adam was stationed in Southern California having moved from Chicago, and found his vision was deteriorating. He was told the LASIK had caused a degenerative eye disease that affects the cornea called keratoconus. As the disease progressed, Adam was referred to Dr. Jonathan Song at the USC Roski Eye Institute and ultimately had to have a corneal transplant in his left eye. Years later his right eye started to deteriorate as well. But this time, Dr. Song engaged his colleague, Dr. Brad Randleman, a refractive surgeon who is an expert in both LASIK and corneal diseases such as keratoconus. Dr. Randleman had been involved in clinical trials since 2008 on a keratoconus treatment called corneal cross-linking (CXL), a non-invasive procedure that can reduce or stop the progression of keratoconus and prevent the need for another corneal transplant. In 2016, USC Roski Eye Institute was the first medical center in the greater Los Angeles area to perform CXL after FDA approval and Adam was our first patient.